B CELL DEPLETION IN DIFFUSE PROGRESSIVE SYSTEMIC SCLEROSIS: SAFETY, SKIN SCORE MODIFICATION AND IL-6 MODULATION IN AN UP TO THIRTY-SIX MONTHS FOLLOW-UP OPEN-LABEL TRIAL